Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 2.3.1.26 extracted from

  • Smith, D.C.; Kroiss, M.; Kebebew, E.; Habra, M.A.; Chugh, R.; Schneider, B.J.; Fassnacht, M.; Jafarinasabian, P.; Ijzerman, M.M.; Lin, V.H.; Mohideen, P.; Naing, A.
    A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma (2020), Invest. New Drugs, 38, 1421-1429.
    View publication on PubMed

Application

Application Comment Organism
medicine treatment of 63 patients with metastatic adrenocortical carcinoma with oral nevanimibe at doses ranging from 1.6 mg/kg/day to 158.5 mg/kg/day. No patients experienced a complete or partial response. 13 of 48 (27%) patients who underwent imaging at 2 months had stable disease, and 4 of these had stable disease for more than 4 months Homo sapiens

Inhibitors

Inhibitors Comment Organism Structure
nevanimibe
-
Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens P35610
-
-